Reaction Steps
To a solution of 5-(tert-Butyl-dimethyl-silanyloxymethyl)-3-(3-fluoro-4-{2-[4-(2-methyl-6-nitro-2,3-dihydro-imidazo[2,1-b]oxazol-2-ylmethyl)-[1,4]diazepan-1-yl]-pyrimidin-5-yl}-phenyl)-oxazolidin-2-one (580 mg, 0.84 mmol) in THF (8.0 mL) was added TBAF (3.3 mL, 3.3 mmol, 1.0 M in THF). The mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc, washed with brine, dried with Na2SO4, purified by flash chromatography to give the title product (100 mg, 21%) as a yellow solid. ESI MS m/z 569 (M+H+); 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 7.60 (dd, J=30, 3.0 Hz, 1H), 7.36 (t, J=20 Hz, 1H), 7.29 (d, J=3.0 Hz, 1H), 7.25 (s, 2H), 4.70 (m, 1H), 4.10 (d, J=25.0 Hz, 1H), 3.95-4.06 (m, 2H), 3.82-3.88 (m, 2H), 3.76 (d, J=23.0 Hz, 1H), 3.64 (dd, J=33, 10.0 Hz, 1H), 3.41-3.58 (m, 2H), 3.31 (bs, 3H), 3.02 (d, J=38.0, 1H), 2.94 (q, J=16.0 Hz, 1H), 2.82-2.84 (m, 1H), 2.70-2.78 (m, 1H), 2.60 (d, J=38.0, 1H), 1.64-1.72 (m, 1H), 1.50-1.58 (m, 1H), 1.48 (s, 3H).
